Main Drug Interaction
Ruxolitinib, a JAK1/JAK2 inhibitor used for myelofibrosis and graft-versus-host disease (GVHD), has no major pharmacokinetic interactions with corticosteroids like prednisone or methylprednisolone. It does not significantly alter steroid metabolism via CYP3A4, and vice versa.[1][2]
Clinical Use Together in GVHD
Ruxolitinib is FDA-approved with steroids for steroid-refractory acute GVHD. Guidelines recommend starting ruxolitinib (5-10 mg twice daily) alongside tapering steroids (e.g., prednisone 1 mg/kg/day), as it boosts response rates to 60-80% versus steroids alone (40-50%). No dose adjustments needed for ruxolitinib when co-administered.[3][4]
Additive Side Effects and Monitoring
Both suppress immunity, raising infection risk (e.g., fungal, viral). Ruxolitinib adds thrombocytopenia and anemia risks to steroid-induced hyperglycemia and osteoporosis. Monitor CBC weekly, blood glucose, and screen for infections like PCP (prophylaxis advised). Reduce ruxolitinib dose by 50% if platelets <50,000/μL.[1][5]
How Long to Watch for Issues
Interactions peak within days of starting; steady-state ruxolitinib reached in 3 days. Taper steroids gradually over weeks to avoid rebound GVHD while maintaining ruxolitinib.[3]
Alternatives if Concerns Arise
If infection risk is high, consider JAK inhibitors like baricitinib (less anemia) or ibrutinib over ruxolitinib with steroids. For mild GVHD, topical steroids alone suffice without systemic ruxolitinib.[4]
[1]: Jakafi (ruxolitinib) Prescribing Information - Incyte
[2]: Drugs.com - Ruxolitinib Interactions
[3]: NCCN Guidelines - Myelofibrosis/GVHD (2023)
[4]: REACH2 Trial - NEJM (2018)
[5]: Lexicomp - Ruxolitinib Monograph